Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of prostate cancer called prostate adenocarcinoma
- People whose cancer falls within a mid-range severity level (Grade Group 2, 3, or 4 out of 5)
- People whose cancer lesion, as seen on MRI scan, is small — no larger than 3ml for a single lesion, or no larger than 1.5ml each if there are two lesions
- People whose cancer has not visibly spread beyond the outer wall of the prostate gland
- People whose cancer has been assessed by the medical team as being fully treatable with a targeted (focal) therapy approach, with an adequate safety margin around the treated area
Who may not be able to join:
- People whose cancer is classified as Grade Group 5 (the most severe grade)
- People whose cancer has visibly spread beyond the outer wall of the prostate gland
- People who have significant prostate cancer in more than two separate areas of the prostate
- People whose cancer is located in a position that makes targeted treatment not possible — for example, at the very tip or base of the prostate, or in another location the treating specialist determines cannot be safely treated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kae Jack Tay, MBBS, Singapore General Hospital
Phone: +65 63214639
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1-year Post-Focal Therapy (FT) clinically significant cancer recurrence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.